NCT01732146View on ClinicalTrials.gov

Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 28, 2013

Primary Completion Date

February 14, 2017

Study Completion Date

February 14, 2017

Conditions
Hypoxic Ischemic Encephalopathy
Interventions
DRUG

erythropoietin Beta

erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery

DRUG

Placebo

Trial Locations (1)

75014

Cochin Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01732146 - Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy | Biotech Hunter | Biotech Hunter